Literature DB >> 6870915

Inhibition of phospholipid degradation and changes of the phospholipid-pattern by desipramine in cultured human fibroblasts.

R Fauster, U Honegger, U Wiesmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6870915     DOI： 10.1016/0006-2952(83)90119-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  5 in total

1.  Inhibition by vitamin E of drug accumulation and of phospholipidosis induced by desipramine and other cationic amphiphilic drugs in human cultured cells.

Authors:  I Scuntaro; U Kientsch; U N Wiesmann; U E Honegger
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function.

Authors:  Meng-Yang Zhu; Patrick B Kyle; Arthur S Hume; Gregory A Ordway
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

3.  Lipidosis-like alterations in cultured macrophages exposed to local anaesthetics.

Authors:  M Jägel; R Lüllmann-Rauch
Journal:  Arch Toxicol       Date:  1984-10       Impact factor: 5.153

4.  Enhanced oxidative phosphorylation in rat liver mitochondria following prolonged in vivo treatment with imipramine.

Authors:  S S Katyare; R R Rajan
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

5.  Cytoprotection of rat hepatocytes by desipramine in a model of simulated ischemia/reperfusion.

Authors:  Jun-Kyu Shin; Jae-Sung Kim
Journal:  Biochem Biophys Rep       Date:  2021-07-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.